Ginkgo Bioworks Holdings, Inc. (DNA)
| Market Cap | 383.64M |
| Revenue (ttm) | 170.16M |
| Net Income (ttm) | -312.76M |
| Shares Out | 56.84M |
| EPS (ttm) | -5.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,908,250 |
| Open | 8.01 |
| Previous Close | 9.71 |
| Day's Range | 6.68 - 8.27 |
| 52-Week Range | 5.00 - 17.58 |
| Beta | 1.56 |
| Analysts | Hold |
| Price Target | 10.50 (+55.56%) |
| Earnings Date | Feb 26, 2026 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms... [Read more]
Financial Performance
In 2025, Ginkgo Bioworks Holdings's revenue was $170.16 million, a decrease of -25.06% compared to the previous year's $227.04 million. Losses were -$312.76 million, -42.83% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DNA stock is "Hold." The 12-month stock price target is $10.5, which is an increase of 55.56% from the latest price.
News
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter
Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business
Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth ...
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it...
Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products
Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Biowor...
Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark
Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis G...
Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Th...
Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach
BOSTON , Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Carnegie-Mellon University (CMU) for an award by the Advanced Research Projects Agency for Healt...
Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
Collaboration reduces time in fermenting complex bacterial strains, enabling continued focus on next-gen biological crop solutions. BOSTON and PLANO, Texas , Dec. 17, 2025 /PRNewswire/ -- Ginkgo Biowo...
ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies
ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
BOSTON , Dec. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARP...
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
BOSTON , Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory...
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
CAMBRIDGE, Mass. , Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has bee...
Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health
BOSTON , Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year ...
Ginkgo Bioworks: Not There Yet
Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and oper...
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. ( DNA) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting...
Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
Ginkgo provides an update on its third quarter financial results BOSTON , Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third qu...
Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure BOSTON , Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA...
Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture
BOSTON , Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of ...
Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON , Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it...
Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases BOSTON , Oct. 23, 2025 /PRNewswire/ ...
Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.
Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions
BOSTON , Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, deriva...
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry
BOSTON , Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entere...
Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth
Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to suppo...